Literature DB >> 21120114

Promising pharmacotherapy on the horizon for nicotine dependence.

Wade H Berrettini1.   

Abstract

Nicotine dependence pharmacotherapy is important to psychiatrists, as epidemiological studies indicate that a majority of individuals with schizophrenia or affective disorders are daily smokers. The epidemiology of nicotine dependence and the efficacy of nicotine dependence pharmacotherapies are reviewed briefly. Then, novel pharmacotherapies for which FDA approval is expected next year are described.

Entities:  

Year:  2005        PMID: 21120114      PMCID: PMC2994239     

Source DB:  PubMed          Journal:  Psychiatry (Edgmont)        ISSN: 1550-5952


  15 in total

1.  Measuring nicotine dependence among high-risk adolescent smokers.

Authors:  A V Prokhorov; U E Pallonen; J L Fava; L Ding; R Niaura
Journal:  Addict Behav       Date:  1996 Jan-Feb       Impact factor: 3.913

2.  Nicotine addiction: a pediatric disease.

Authors:  D A Kessler; S L Natanblut; J P Wilkenfeld; C C Lorraine; S L Mayl; I B Bernstein; L Thompson
Journal:  J Pediatr       Date:  1997-04       Impact factor: 4.406

3.  Reliability of the Fagerstrom Tolerance Questionnaire and the Fagerstrom Test for Nicotine Dependence.

Authors:  C S Pomerleau; S M Carton; M L Lutzke; K A Flessland; O F Pomerleau
Journal:  Addict Behav       Date:  1994 Jan-Feb       Impact factor: 3.913

4.  Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.

Authors:  Jotham W Coe; Paige R Brooks; Michael G Vetelino; Michael C Wirtz; Eric P Arnold; Jianhua Huang; Steven B Sands; Thomas I Davis; Lorraine A Lebel; Carol B Fox; Alka Shrikhande; James H Heym; Eric Schaeffer; Hans Rollema; Yi Lu; Robert S Mansbach; Leslie K Chambers; Charles C Rovetti; David W Schulz; F David Tingley; Brian T O'Neill
Journal:  J Med Chem       Date:  2005-05-19       Impact factor: 7.446

5.  Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence.

Authors:  A Castañé; E Valjent; C Ledent; M Parmentier; R Maldonado; O Valverde
Journal:  Neuropharmacology       Date:  2002-10       Impact factor: 5.250

6.  Nicotine dependence in the United States: prevalence, trends, and smoking persistence.

Authors:  N Breslau; E O Johnson; E Hiripi; R Kessler
Journal:  Arch Gen Psychiatry       Date:  2001-09

7.  Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences.

Authors:  Bernard Le Foll; Steven R Goldberg
Journal:  Neuroreport       Date:  2004-09-15       Impact factor: 1.837

8.  Initiation of daily smoking and nicotine dependence in schizophrenia and mood disorders.

Authors:  Jose de Leon; Francisco J Diaz; Thea Rogers; Debra Browne; Lori Dinsmore
Journal:  Schizophr Res       Date:  2002-07-01       Impact factor: 4.939

9.  Advances in pharmacotherapy for tobacco dependence.

Authors:  Jonathan Foulds; Michael Burke; Michael Steinberg; Jill M Williams; Douglas M Ziedonis
Journal:  Expert Opin Emerg Drugs       Date:  2004-05       Impact factor: 4.191

10.  SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats.

Authors:  C Cohen; G Perrault; C Voltz; R Steinberg; P Soubrié
Journal:  Behav Pharmacol       Date:  2002-09       Impact factor: 2.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.